GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OTCPK:MBGPF) » Definitions » Price-to-Owner-Earnings

MBGPF (Moberg Pharma AB) Price-to-Owner-Earnings : (As of May. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Moberg Pharma AB Price-to-Owner-Earnings?

As of today (2025-05-02), Moberg Pharma AB's share price is $0.81995. Moberg Pharma AB does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Moberg Pharma AB's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Moberg Pharma AB was 1545.44. The lowest was 0.54. And the median was 14.55.


MBGPF's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-02), Moberg Pharma AB's share price is $0.81995. Moberg Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.51. Therefore, Moberg Pharma AB's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-02), Moberg Pharma AB's share price is $0.81995. Moberg Pharma AB's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.51. Therefore, Moberg Pharma AB's PE Ratio without NRI for today is At Loss.

During the past 13 years, Moberg Pharma AB's highest PE Ratio without NRI was 716.95. The lowest was 0.00. And the median was 21.05.


Moberg Pharma AB Price-to-Owner-Earnings Historical Data

The historical data trend for Moberg Pharma AB's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Price-to-Owner-Earnings Chart

Moberg Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Moberg Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Moberg Pharma AB's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Price-to-Owner-Earnings falls into.


;
;

Moberg Pharma AB Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Moberg Pharma AB's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.81995/-0.04
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moberg Pharma AB  (OTCPK:MBGPF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Moberg Pharma AB Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Moberg Pharma AB's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Moberg Pharma AB Business Description

Traded in Other Exchanges
Address
Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of compounds. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.